// App-Quantinova.ai

4534 : A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC).

Researchers

Presenter

  • Andrea B. Apolo

Principal Investigators

  • Deneise C Francis

  • Lisa M Cordes

  • Marilise Berninger

  • Elizabeth Lamping

  • Rene Costello

  • Jane B. Trepel

  • Maria J Merino

  • Les Folio

  • Maria Liza Lindenberg

  • William Douglas Figg

  • Seth M. Steinberg

  • John Joseph Wright

  • Ravi Amrit Madan

  • Yangmin M. Ning

  • James L. Gulley

  • Donald P. Bottaro

  • William L. Dahut

  • Piyush K. Agarwal

Medical Centers

  • Gastrointestinal Malignancies Section, Center for Cancer Research, National Cancer Institute at the National Institutes of Health, Bethesda, MD

  • Division of Cancer Prevention, National Cancer Institute at the National Institutes of Health, Bethesda, MD

  • Genitourinary Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD

  • National Institute of Health, Bethesda, MD

  • National Cancer Institute, Bethesda, MD

  • Center for Cancer Research, National Cancer Institute, Bethesda, MD

  • Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD

  • Laboratory of Tumor Immunology and Biology, National Cancer Institute at the National Institutes of Health, Bethesda, MD

  • Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

  • Clinical Pharmacology Program, National Cancer Institute at the National Institutes of Health, Bethesda, MD

  • Biostatistics and Data Management Section, National Cancer Institute at the National Institutes of Health, Bethesda, MD

  • FDA, Silver Spring, MD

  • Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Cabozantinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01688999

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved